The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis

Respirology

Volumn 10, Issue 5, 2005, Pages 643-648

  Yen, Kenneth T ^a   Putzke, John D ^a   Staats, Bruce A ^b   Burger, Charles D ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Bronchodilators; Chronic airflow obstruction; Lung diseases; Lymphangioleiomyomatosis; Retrospective studies

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL;

ADULT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; LUNG VOLUME; LYMPHANGIOLEIOMYOMATOSIS; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; UNITED STATES; ADOLESCENT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; HOSPITALIZATION; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PROGNOSIS;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BRONCHODILATOR AGENTS; FEMALE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 33644843695     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2005.00762.x     Document Type: Review

References (23)

1. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis: a review. Am. J. Pathol. 1975; 79: 348-82.
2. McCarty KS Jr, Mossler JA, McLelland R, Sieker HO. Pulmonary lymphangiomyomatosis responsive to progesterone. N. Engl. J. Med. 1980; 303: 1461-5.
3. Matsui K, Takeda K, Yu ZX et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy: an immunohistochemical study. Am. J. Respir. Crit. Care Med. 2000; 161: 1002-9.
4. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol. 1999; 21: 327-36.
5. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am. J. Hum. Genet. 1998; 62: 810-15.
6. Astrinidis A, Khare L, Carsillo T et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J. Med. Genet. 2000; 37: 55-7.
7. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 2000; 97: 6085-90.
8. Goncharova EA, Goncharov DA, Eszterhas A et al. Tuberin regulates p70, S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 2002; 277: 30958-67.
9. Evans SE, Colby TV, Ryu JH, Limper AH. Transforming growth factor-b1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis. Chest 2004; 125: 1063-70.
10. Chu SC, Horiba K, Usuki J et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115: 1041-52.
11. Taveira-DaSilva AM, Hedin C, Stylianou MP et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 2001; 164: 1072-6.
12. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am. Rev. Respir. Dis. 1991; 144: 1202-18.
13. American Thoracic Society. Standardization of spirometry: 1987 update. Am. Rev. Respir. Dis. 1987; 136: 1285-98.
14. Miller A, Thornton JC, Warshaw R, Anderson H, Teirstein AS, Selikoff IJ. Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state: predicted values, lower limits of normal and frequencies of abnormality by smoking history. Am. Rev. Respir. Dis. 1983; 127: 270-7.
15. Miller A, Thornton JC, Warshaw R, Bernstein J, Selikoff IJ, Teirstein AS. Mean and instantaneous expiratory flows, FVC and FEV1: prediction equations from a probability sample of Michigan, a large industrial state. Bull. Eur. Physiopathol. Respir. 1986; 22: 589-97.
16. SPSS. SPSS for Windows, Version 11.0. SPSS, Chicago.
17. Crausman RS, Jennings CA, Mortenson RL, Ackerson LM, Irvin CG, King TE Jr. Lymphangioleiomyomatosis: the pathophysiology of diminished exercise capacity. Am. J. Respir. Crit. Care Med. 1996; 153: 1368-76.
18. Burger CD, Hyatt RE, Staats BA. Pulmonary mechanics in lymphangioleiomyomatosis. Am. Rev. Respir. Dis. 1991; 143: 1030-3.
19. Urban T, Lazor R, Lacronique J et al. for the Groupe d'Etudes et de Recherche sur les Maladies 'Orphelines' Pulmonaires (GERM'O'P). Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Medicine (Baltimore) 1999; 78: 321-37.
20. Oh YM, Mo EK, Jang SH et al. Pulmonary lymphangioleiomyomatosis in Korea. Thorax 1999; 54: 618-21.
21. 1. The Lung Health Study. JAMA 1994; 272: 1497-505.
22. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am. J. Respir. Crit. Care Med. 1999; 160: 628-33.
23. 1 decline in pulmonary lymphangioleiomyomatosis. Respir. Med. 2004; 98: 536-41.